Edgen Stock·Oct 02 2025, 14:23戻る
戻る
CRISPR Therapeutics Maintains "Outperform" Rating Amidst Phase 2 Thromboembolism Trial Initiation
Edgen Stock·Oct 02 2025, 14:23
[1] BMO Reaffirms Outperform on CRISPR Therapeutics (CRSP) After Sirius Collaboration (https://finance.yahoo.com/news/bmo-reaffirms- ...)[2] BMO Capital reiterates Outperform on CRISPR Therapeutics stock, sees potential in thrombosis market - Investing.com (https://www.investing.com/news/stock-market-n ...)[3] CRISPR Therapeutics Advances Gene-Editing Pipeline Amidst Accelerating Casgevy Sales (https://www.fool.com/investing/2025/09/30/cou ...)